The conversation discusses hair regrowth progress from November 2023 to April 2024 using 1mg finasteride, 5% minoxidil, and weekly dermarolling. The consensus is that there is some improvement and increased density, with expectations of further progress.
The user changed their hair loss treatment in October/November, experienced increased shedding, and now sees no new hair growth, with a worsening condition and a possible bald spot. They also have severe seborrheic dermatitis, which may be affecting their scalp and hair loss.
Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.
A user's experience with microneedling monotherapy and potential treatments such as finasteride, minoxidil, Stemoxydine, rosemary oil, peppermint oil, and RU58841 for reversing hair loss.
The user had a hair transplant in 2020 and later learned they needed to continue medication for hair loss. They shared a 5-month timelapse video of their hair regrowth using topical finasteride/minoxidil, microneedling every 3 weeks, and ketoconazole.
Hair regrowth from treatments like finasteride, dutasteride, and minoxidil can take several years, with most visible results appearing within 1-2 years and potential improvements continuing up to 10 years. Consistency and patience are crucial for achieving maximum hair thickness, as hair miniaturization and regrowth are gradual processes.
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.
Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.
Cyclosporine A is discussed as a powerful hair growth stimulant, potentially more effective than minoxidil, but concerns about safety and side effects, including cancer risk, limit its use. The conversation highlights the need for further research and experimentation with topical application, despite its risks.
Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.
The user is using dutasteride, estradiol cypionate, microneedling, oral minoxidil, and plans to add ketoconazole for hair regrowth. They are questioning if the improvement is due to actual regrowth or just better photo angles.
RepliCel's potential hair loss treatment may cost around $1000 and aims to protect hair follicles from DHT, possibly reversing some miniaturization. It is not considered a cure and may be most effective in early hair loss stages, with its main advantage over finasteride being the lack of sexual side effects.
The user shared their hair regrowth progress using a regimen including omega-3, flaxseed, EGCG, green tea, zinc, copper, probiotics, microneedling, topical finasteride, and minoxidil. Other users expressed skepticism about the effectiveness of the regimen, suggesting more proven treatments or considering a hair transplant.
The potential hair regrowth benefits of ASC-J9, a synthetic modified version of curcumin that is said to be more effective than Minoxidil and Finasteride. Reports from users suggest good thickening and temple regrowth with topical use at 0.025% concentration.
The conversation is about a user interested in participating in hair cloning clinical trials due to their fine hair and previous positive experience with clinical trials. They are seeking information on how to volunteer for such trials.
A 29-year-old shared their hair recovery progress using a liposomal topical finasteride/minoxidil solution, LLLT helmet, and vitamins, noting that transplants were only on the hairline. They highlighted the effectiveness of their regimen and addressed skepticism with photos.
The conversation discusses the use of Verteporfin in hair loss treatment. It suggests that Verteporfin could potentially regenerate hair follicles instead of forming scars, providing an unlimited donor supply for hair transplants.
Hair loss progress after 12 months using minoxidil, finasteride, and microneedling. Goal is to maintain and improve hair until old enough for hair transplant.
HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.
The conversation discusses hair regrowth progress using finasteride, minoxidil, dutasteride, ketoconazole, microneedling, and multivitamins. The user shares their journey and receives advice on haircuts and additional treatments like PRP and RU58841.
The conversation is about experimenting with topical exosomes for hair loss treatment, alongside microneedling, Happy Head's gel-like topical, and Ordinary's hair serum. The user also mentions the availability of treatments like latanoprost and Redensyl.
The user reports slow and steady hair regrowth using Finasteride (1.25mg) and topical Minoxidil (Rogaine, 2x/day), along with occasional use of Nizoral. They have stopped dermarolling.
The conversation discusses biannual SCUBE3 injections and microneedling as treatments for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.